Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: A single institution experience of 151 Asian patients

Bone Marrow Transplantation

Volumn 45, Issue 6, 2010, Pages 1031-1037

  Linn, Y C ^a   Phang, C Y ^b   Lim, T J ^b   Chong, S F ^a   Heng, K K ^a   Lee, J J ^a   Loh, Y ^a   Hwang, W ^a   Goh, Y T ^a   Koh, M ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b HEALTH SCIENCES AUTHORITY   (Singapore)

Author keywords

HLA full matched sibling transplant; KIR ligand; missing ligand model; NK alloreactivity

Indexed keywords

CYCLOSPORIN A; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ALLOIMMUNITY; ARTICLE; ASIAN; CANCER STAGING; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR SELECTION; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HOMOZYGOSITY; HUMAN; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NATURAL KILLER T CELL; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIBLING; COHORT ANALYSIS; HISTOCOMPATIBILITY TEST; LEUKEMIA; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; REGISTER; SINGAPORE; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA; LIGANDS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROGNOSIS; RECEPTORS, KIR; REGISTRIES; RETROSPECTIVE STUDIES; SIBLINGS; SINGAPORE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77954863151     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.303     Document Type: Article

References (25)

1. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
2. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
3. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650.
4. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-440.
5. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G et al. KIR-ligand incompatibility in the graft-versushost direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23: 492-500.
6. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
7. Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004; 103: 2860-2861.
8. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825-3827.
9. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
10. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007; 97: 539-542.
11. Stern M, Paulussen M, Rischewski J, Tichelli A, Gratwohl A. Missing ligand model in autologous stem cell transplantation. Br J Cancer 2008; 98: 852-853.
12. Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M et al. Survival of AML patients receiving HLAmatched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 2007; 39: 417-424.
13. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148: 520-528.
14. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828-836.
15. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-5061.
16. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLAidentical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-1526.
17. Ruggeri L, Capanni M, Mancusi A, Urbani E, Perruccio K, Burchielli E et al. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation. Blood Cells Mol Dis 2004; 33: 216-221. (Pubitemid 39446489)
18. Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood 2008; 112: 708-710.
19. Beelen DW, Quabeck K, Kaiser B, Wiefelsputz J, Scheulen ME, Graeven U et al. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 1990; 50: 421-427.
20. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
21. Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003; 123: 323-326.
22. Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 2004; 103: 3860-3868.
23. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113: 3875-3884.
24. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008; 111: 3155-3162.
25. Berg M, Lundqvist A, McCoy Jr P, Samsel L, Fan Y, Tawab A et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341-355.